Research progress on the antihypertensive effect of sodium-glucose synergistic transporter 2 inhibitors
10.3760/cma.j.cn114798-20220223-00126
- VernacularTitle:钠-葡萄糖协同转运蛋白2抑制剂降压作用的研究进展
- Author:
Xiuqi QIAO
1
;
Jiaming CAO
;
Lina ZHANG
;
Qi PAN
Author Information
1. 北京医院内分泌科 国家老年医学中心 中国医学科学院老年医学研究院，北京100730
- Keywords:
Sodium-glucose transport proteins;
Hypotension, controlled;
Diabetes mellitus
- From:
Chinese Journal of General Practitioners
2022;21(6):584-587
- CountryChina
- Language:Chinese
-
Abstract:
Diabetes mellitus is a chronic metabolic disease, in which the abnormality of glucose and lipid metabolism may cause multisystem damage. Sodium-glucose synergistic transporter 2 (SGLT2) inhibitors are a novel type of hypoglycemic drug that can lower blood sugar level by inhibiting the absorption of glucose through renal tubules. Studies have shown that SGLT2 inhibitors also have a lowering effect on blood pressure, but the mechanism is not fully elucidated. In this article the hypotensive effects of SGLT2 inhibitors and possible mechanisms are reviewed.
